KRE vs XBI
SPDR S&P Regional Banking ETF vs SPDR S&P Biotech ETF
- • KRE pays a higher dividend yield (2.24%).
Side-by-side metrics
| Metric | KRE | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.35% | 0.35% |
Dividend yield Trailing 12-month yield. | 2.24% | 0.35% |
AUM Assets under management — bigger funds are typically more liquid. | $4.01B | $10.92B |
YTD return | 15.29% | 28.80% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.97 | 1.01 |
P/E ratio | 12.13 | — |
Last price | $72.81 | $156.41 |
Inception | — | — |
Issuer | State Street | State Street |
KRE top holdings
| GBCI | Glacier Bancorp Inc | 1.20% |
| UCB | United Community Banks Inc | 1.18% |
| TCBI | Texas Capital Bancshares Inc | 1.18% |
| OZK | Bank OZK | 1.17% |
| EBC | Eastern Bankshares Inc Ordinary Shares | 1.16% |
| COLB | Columbia Banking System Inc | 1.16% |
| UBSI | United Bankshares Inc | 1.16% |
| VLY | Valley National Bancorp | 1.16% |
| PNFP | Pinnacle Financial Partners Inc | 1.16% |
| FIBK | First Interstate BancSystem Inc | 1.15% |
XBI top holdings
| MRNA | Moderna Inc | 2.37% |
| NTRA | Natera Inc | 1.82% |
| HALO | Halozyme Therapeutics Inc | 1.77% |
| TWST | Twist Bioscience Corp | 1.77% |
| BIIB | Biogen Inc | 1.75% |
| AMGN | Amgen Inc | 1.73% |
| EXEL | Exelixis Inc | 1.73% |
| UTHR | United Therapeutics Corp | 1.72% |
| ABBV | AbbVie Inc | 1.71% |
| GILD | Gilead Sciences Inc | 1.70% |
About KRE
KRE (SPDR S&P Regional Banking ETF) is US regional bank stocks. Managed by State Street, the fund carries $4.0B in assets under management, an expense ratio of 0.35%, a dividend yield of 2.24%. Its largest holding is Glacier Bancorp Inc (GBCI), which represents 1.2% of the portfolio. Financial Services is the fund's largest sector exposure at 100.0%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.9B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.35%. Its largest holding is Moderna Inc (MRNA), which represents 2.4% of the portfolio. Financial Services is the fund's largest sector exposure at 0.6%.